Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia.
D000328:Adult; D000367:Age Factors; D000368:Aged; D001712:Biperiden / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008781:Methyltyrosines / Q000009:adverse effects; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000503:physiopathology*; D010275:Parasympathetic Nervous System / Q000503:physiopathology*; D010830:Physostigmine / Q000009:adverse effects / Q000627:therapeutic use; D012601:Scopolamine / Q000627:therapeutic use; D013997:Time Factors
D008781:Methyltyrosines; D001712:Biperiden; D004295:Dihydroxyphenylalanine; D010830:Physostigmine; D012601:Scopolamine; D004298:Dopamine